Abstract
The goal of treatment in stable coronary artery disease is to improve prognosis and quality of life of the patients. International Guidelines support revascularization procedures for symptomatic patients unresponsive to optimal medical treatment. Previous studies demonstrated, in fact, the therapeutic efficacy of coronary angioplasty in reducing angina and improving the functional capacity of these patients. The ORBITA study, recently published, challenged these assertions by demonstrating the lack of benefit of angioplasty over placebo in terms of effort tolerance in a population of patients with single-vessel coronary artery disease. What lesson could we learn from the ORBITA study?